FDAnews Drug Daily Bulletin
June 8, 2012 | Vol. 9 No. 113
The House appropriations subcommittee that oversees FDA funding recommends fiscal 2013 appropriations that would slightly reduce agency spending.
The Senate-passed omnibus FDA user fee bill includes a proposed track-and-track system, but lawmakers need to hammer out details with the agency and stakeholders or risk seeing the proposal jettisoned from a final bill.
Rogue online pharmacies looking to cash in on drugs in short supply are peddling counterfeit versions of Teva’s attention-deficit/hyperactivity disorder drug Adderall, the FDA warns.
The U.S. Food and Drug Administration said that a Novartis AG unit is recalling a three-month birth-control regimen sold in the U.S. because of a packing error.
The coming weeks may bring a victory in the long war against the human immunodeficiency virus (HIV), which causes AIDS.
Pfizer’s 20-person surveillance testing group in Groton, part of the company’s Scientific Laboratory Services team that tests products manufactured by contractors, will be moving to Singapore sometime next year.
A new test that analyzes tumors for more than 200 genes is attracting interest among drug companies and researchers, reflecting how genetic information is transforming drug development and treatment for cancer.
Drug companies used to produce branded, patent-protected medicine or they produced generic copies and rarely both, especially in the United States.
Patients suffering from the most severe form of childhood arthritis were less likely to experience a flare up in the disease when using Novartis’ drug Ilaris compared to a placebo.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.